Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Somavert | Pegvisomant | acromegaly | Do not list | Complete | ||
Remodulin | Treprostinil sodium | Pulmonary arterial hypertension (NYHA Class III and IV patients) | List with clinical criteria and/or conditions | Complete | ||
Trelstar | Triptorelin pamoate | Cancer, prostate | List in a similar manner to other drugs in class | Complete | ||
Amevive | Alefacept | Psoriasis, moderate to severe chronic plaque | Do not list | Complete | ||
Pantoloc M | Pantoprazole magnesium | Gastric acid secretion, reduction of | List in a similar manner to other drugs in class | Complete | ||
DuoTrav | Travoprost and timolol maleate | Glaucoma | List with clinical criteria and/or conditions | Complete | ||
Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
VFEND | Voriconazole | Candidemia | List with clinical criteria and/or conditions | Complete | ||
Lantus | Insulin glargine (rDNA origin) | Diabetes mellitus, Type 1 & 2 | Do not list | Complete | ||
Fosavance | Alendronate sodium/cholecalciferol | Osteoporosis | Do not list | Complete |